Press release
United Therapeutics Releases Its First Corporate Responsibility Report
Report available at corporateresponsibility.unither.com SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 /PRNewswire/ -- United Therapeutics
About this update from United Therapeutics Corporation
[{"type":"text","content":"Report available at corporateresponsibility.unither.com\n\n\nSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its initial Corporate Responsibility Report with primarily 2019 data and selected 2020 highlights, providing stakeholders important information regarding the company's commitment to environmental, social, and governance (ESG) priorities. \n\"Environmental sensitivity and corporate responsibility have been part of our DNA since our inception,\" said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. \"In light of growing interest in ESG from investors and other stakeholders, we are pleased to share our corporate responsibility achievements in this inaugural report.\"\nUnited Therapeutics developed its initial Corporate Responsibility Report with guidance from members of its Board of Directors and the frameworks provided by both the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB). United Therapeutics is using applicable GRI and SASB metrics to measure its performance. \nUnited Therapeutics plans to continue to report on its corporate responsibility efforts on an annual basis and plans to issue its next report around mid-year 2021.\nFind the full report at corporateresponsibility.unither.com.\nAbout United Therapeutics \nUnited Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.\nThrough our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.\nForward-looking Statements \nStatements included in this press...